Gene · 4921
DDR2: discoidin domain receptor tyrosine kinase 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. DDR2: discoidin domain receptor tyrosine kinase 2. Genes, record 4921. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4921
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16832 | Discoidin domain-containing receptor 2 | 855 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents74
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 43945 | Q16832 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 43946 | Q16832 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8319 | Q16832 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8514 | Q16832 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 4072 | Q16832 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 4073 | Q16832 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1234 | Q16832 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6122 | Q16832 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1234 | Q16832 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6122 | Q16832 | Espacenet |
1 to 10 of 74
See all 74 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| REGORAFENIB | CHEMBL1946170 | Discoidin domain-containing receptor 2 inhibitor | INHIBITOR |
Source ChEMBL
Trials249
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07559864 | REGORAFENIB | PHASE2 | ClinicalTrials.gov | |
| NCT07537985 | REGORAFENIB | ClinicalTrials.gov | ||
| NCT07514455 | REGORAFENIB | PHASE2 | ClinicalTrials.gov | |
| NCT07514429 | REGORAFENIB | PHASE2 | ClinicalTrials.gov | |
| NCT07501351 | REGORAFENIB | PHASE2 | ClinicalTrials.gov | |
| NCT07495579 | REGORAFENIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463248 | REGORAFENIB | PHASE2 | ClinicalTrials.gov | |
| NCT07379047 | REGORAFENIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07343791 | REGORAFENIB | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07328009 | REGORAFENIB | PHASE2 | ClinicalTrials.gov |
1 to 10 of 249
See all 249 trialsNIH grants1,545
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | DDR2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 34 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 19 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 15 | 2025 |
| P30AR069620 | Michigan Integrative Musculoskeletal Health Core Center (Overall Application) | 9 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 8 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 8 | 2025 |
| R01DE029465 | Discoidin Domain Receptor 2, β1 Integrins and ECM Control of Bone Formation | 8 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 7 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 6 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 6 | 2025 |
1 to 10 of 1,545Source NIH's project files
See all 1,545 nih grantsPapers2,653
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Donor-dependent heterogeneity and matrix-remodeling transcriptional programs in COL2A1-variant urine-derived cell cultures with IGF1-associated cell-state shifts. | Front Cell Dev Biol | 2026 | 42745831 | PubTator, text mining | PubMed |
| Quantitative structural alterations of collagen dictate discoidin domain receptor 2 binding efficacy and CAL-27 cell adhesion behaviors. | Int J Biol Macromol | 2026 | 42722254 | PubTator, text mining | PubMed |
| Vascular adventitial cells and vascular remodeling: when a harp of thousand strings does not keep in tune so long. | Front Physiol | 2026 | 42707986 | PubTator, text mining | PubMed |
| Prominent Myxoid and Collagenous Stromal Patterns in Dedifferentiated Liposarcoma: A Comparative Analysis of Immunophenotypic and Genomic Profiles. | Anticancer Res | 2026 | 42674680 | PubTator, text mining | PubMed |
| Type I collagen matrix signaling in cancer: receptor sensing and mechanotransduction. | Cell Signal | 2026 | 42660397 | PubTator, text mining | PubMed |
| Long Non-Coding RNAs and Circular RNAs in the Pathobiology of T-Cell Lymphoma. | Cancers (Basel) | 2026 | 42649850 | PubTator, text mining | PubMed |
| Roles of integrin β1 and discoidin domain receptor 2 in cranial regeneration and skeletal progenitor cell function. | Int J Oral Sci | 2026 | 42613320 | PubTator, text mining | PubMed |
| Subcellular proteomic analysis of the DDR2 interactome in a neuronal cell model exposed to Aβ42. | Biochim Biophys Acta Proteins Proteom | 2026 | 42612957 | PubTator, text mining | PubMed |
| SERPINH1 expression represents a reliable biomarker of human breast cancer aggressiveness. | Biol Direct | 2026 | 42464413 | PubTator, text mining | PubMed |
| Characterization of white adipocyte heterogeneity using data-driven microscopy. | Int J Obes (Lond) | 2026 | 42420601 | PubTator, text mining | PubMed |
1 to 10 of 2,653
See all 2,653 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4921
GET https://conductscience.org/api/genes/v1/4921/patents?page=2